Literature DB >> 29140566

Mesenchymal Stem Cell Preparation and Transfection-free Ferumoxytol Labeling for MRI Cell Tracking.

Li Liu1,2, Chien Ho1.   

Abstract

Mesenchymal stem cells (MSCs) are multipotent cells and are the most widely studied cell type for stem cell therapies. In vivo cell tracking of MSCs labeled with an FDA-approved superparamagnetic iron-oxide (SPIO) particle by magnetic resonance imaging (MRI) provides essential information, e.g., MSC engraftment, survival, and fate, thus improving cell therapy accuracy. However, current methodology for labeling MSCs with Ferumoxytol (Feraheme® ), the only FDA-approved SPIO particle, needs transfection agents. This unit describes a new "bio-mimicry" protocol to prepare more native MSCs by using more "in vivo environment" of MSCs, so that the phagocytic activity of cultured MSCs is restored and expanded MSCs can be labeled with Ferumoxytol, without the need for transfection agents and/or electroporation. Moreover, MSCs re-size to a more native size, reducing from 32.0 to 19.5 μm. The MSCs prepared from this protocol retain more native properties and would be useful for biomedical applications and MSC-tracking studies by MRI. © 2017 by John Wiley & Sons, Inc.
Copyright © 2017 John Wiley & Sons, Inc.

Entities:  

Keywords:  Ferumoxytol (Feraheme®); magnetic resonance imaging; mesenchymal stem cells; stem cell culture and expansion; stem cell tracking

Mesh:

Substances:

Year:  2017        PMID: 29140566      PMCID: PMC5699515          DOI: 10.1002/cpsc.38

Source DB:  PubMed          Journal:  Curr Protoc Stem Cell Biol        ISSN: 1938-8969


  36 in total

1.  A new nano-sized iron oxide particle with high sensitivity for cellular magnetic resonance imaging.

Authors:  Chih-Lung Chen; Haosen Zhang; Qing Ye; Wen-Yuan Hsieh; T Kevin Hitchens; Hsin-Hsin Shen; Li Liu; Yi-Jen Wu; Lesley M Foley; Shian-Jy Wang; Chien Ho
Journal:  Mol Imaging Biol       Date:  2011-10       Impact factor: 3.488

2.  Concise review: optimizing expansion of bone marrow mesenchymal stem/stromal cells for clinical applications.

Authors:  Allison I Hoch; J Kent Leach
Journal:  Stem Cells Transl Med       Date:  2015-04       Impact factor: 6.940

3.  Effect of transendocardial delivery of autologous bone marrow mononuclear cells on functional capacity, left ventricular function, and perfusion in chronic heart failure: the FOCUS-CCTRN trial.

Authors:  Emerson C Perin; James T Willerson; Carl J Pepine; Timothy D Henry; Stephen G Ellis; David X M Zhao; Guilherme V Silva; Dejian Lai; James D Thomas; Marvin W Kronenberg; A Daniel Martin; R David Anderson; Jay H Traverse; Marc S Penn; Saif Anwaruddin; Antonis K Hatzopoulos; Adrian P Gee; Doris A Taylor; Christopher R Cogle; Deirdre Smith; Lynette Westbrook; James Chen; Eileen Handberg; Rachel E Olson; Carrie Geither; Sherry Bowman; Judy Francescon; Sarah Baraniuk; Linda B Piller; Lara M Simpson; Catalin Loghin; David Aguilar; Sara Richman; Claudia Zierold; Judy Bettencourt; Shelly L Sayre; Rachel W Vojvodic; Sonia I Skarlatos; David J Gordon; Ray F Ebert; Minjung Kwak; Lemuel A Moyé; Robert D Simari
Journal:  JAMA       Date:  2012-03-24       Impact factor: 56.272

Review 4.  "Mesenchymal" stem cells.

Authors:  Paolo Bianco
Journal:  Annu Rev Cell Dev Biol       Date:  2014-08-18       Impact factor: 13.827

5.  Iron administration before stem cell harvest enables MR imaging tracking after transplantation.

Authors:  Aman Khurana; Fanny Chapelin; Graham Beck; Olga D Lenkov; Jessica Donig; Hossein Nejadnik; Solomon Messing; Nikita Derugin; Ray Chun-Fai Chan; Amitabh Gaur; Barbara Sennino; Donald M McDonald; Paul J Kempen; Grigory A Tikhomirov; Jianghong Rao; Heike E Daldrup-Link
Journal:  Radiology       Date:  2013-07-12       Impact factor: 11.105

6.  Isolation of human mesenchymal stromal cells is more efficient by red blood cell lysis.

Authors:  P Horn; S Bork; A Diehlmann; T Walenda; V Eckstein; A D Ho; W Wagner
Journal:  Cytotherapy       Date:  2008       Impact factor: 5.414

7.  Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: the TAC-HFT randomized trial.

Authors:  Alan W Heldman; Darcy L DiFede; Joel E Fishman; Juan P Zambrano; Barry H Trachtenberg; Vasileios Karantalis; Muzammil Mushtaq; Adam R Williams; Viky Y Suncion; Ian K McNiece; Eduard Ghersin; Victor Soto; Gustavo Lopera; Roberto Miki; Howard Willens; Robert Hendel; Raul Mitrani; Pradip Pattany; Gary Feigenbaum; Behzad Oskouei; John Byrnes; Maureen H Lowery; Julio Sierra; Mariesty V Pujol; Cindy Delgado; Phillip J Gonzalez; Jose E Rodriguez; Luiza Lima Bagno; Didier Rouy; Peter Altman; Cheryl Wong Po Foo; Jose da Silva; Erica Anderson; Richard Schwarz; Adam Mendizabal; Joshua M Hare
Journal:  JAMA       Date:  2014-01-01       Impact factor: 56.272

8.  Self-assembling nanocomplexes by combining ferumoxytol, heparin and protamine for cell tracking by magnetic resonance imaging.

Authors:  Mya S Thu; L Henry Bryant; Tiziana Coppola; E Kay Jordan; Matthew D Budde; Bobbi K Lewis; Aneeka Chaudhry; Jiaqiang Ren; Nadimpalli Ravi S Varma; Ali S Arbab; Joseph A Frank
Journal:  Nat Med       Date:  2012-02-26       Impact factor: 53.440

9.  Human mesenchymal stem cell-replicative senescence and oxidative stress are closely linked to aneuploidy.

Authors:  J C Estrada; Y Torres; A Benguría; A Dopazo; E Roche; L Carrera-Quintanar; R A Pérez; J A Enríquez; R Torres; J C Ramírez; E Samper; A Bernad
Journal:  Cell Death Dis       Date:  2013-06-27       Impact factor: 8.469

10.  Comparative Evaluation of Human Mesenchymal Stem Cells of Fetal (Wharton's Jelly) and Adult (Adipose Tissue) Origin during Prolonged In Vitro Expansion: Considerations for Cytotherapy.

Authors:  I Christodoulou; F N Kolisis; D Papaevangeliou; V Zoumpourlis
Journal:  Stem Cells Int       Date:  2013-03-03       Impact factor: 5.443

View more
  2 in total

1.  Induction of mesenchymal stem cell‑like transformation in rat primary glial cells using hypoxia, mild hypothermia and growth factors.

Authors:  Huiping Wei; Wenyun Zhou; Guozhu Hu; Chunhua Shi
Journal:  Mol Med Rep       Date:  2020-12-10       Impact factor: 2.952

Review 2.  Repurposing ferumoxytol: Diagnostic and therapeutic applications of an FDA-approved nanoparticle.

Authors:  Yue Huang; Jessica C Hsu; Hyun Koo; David P Cormode
Journal:  Theranostics       Date:  2022-01-01       Impact factor: 11.600

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.